
|Videos|August 18, 2017
Dr. Feldman on Remaining Challenges With Biomarkers in Prostate Cancer
Author(s)Adam Scott Feldman, MD, MPH
Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.
Advertisement
Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.
There is a plethora of research on biomarkers, but the ones that actually affect clinical care is quite small, says Feldman.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
5




































































